

Curriculum Vitae

**CV must be written in English*

Personal Information



Title (i.e. Prof., Dr., etc.)	Prof.
Name (First / Middle / Last)	Robert Venning Bryant
Degree (i.e. MD, MSc, PhD, etc.)	MBBS FRACP MScR PhD
Country	Australia
Affiliation	The Queen Elizabeth Hospital, Adelaide University

Educational Background

- 2019 Doctor of Philosophy (PhD) (University Medal)
School of Medicine, Faculty of Health Sciences, University of Adelaide
- 2015 Master of Science by Research (MScR)
Linacre College, University of Oxford, Oxford, United Kingdom
- 2013 Fellowship of the Royal Australasian College of Physicians (FRACP)
Gastroenterology and Hepatology
Royal Australasian College of Physicians
- 2005 Bachelor of Medicine, Bachelor of Surgery (MBBS)
University of Adelaide

Professional Experience

1. Head of Inflammatory Bowel Disease, The Queen Elizabeth Hospital, Adelaide, South Australia
2. Clinical Professor, Adelaide University, Adelaide, South Australia
3. Research Lead, Inflammatory Bowel Disease Research Group, The Basil Hetzel Institute, Woodville, South Australia
4. Director and co-founder, BiomeBank, Microbial Therapeutics Company, Adelaide, South Australia

Professional Organizations

1. Department of Gastroenterology and Hepatology
The Queen Elizabeth Hospital
Woodville Rd, Woodville South, South Australia 5011
2. School of Medicine, Faculty of Health Sciences, University of Adelaide
North Terrace, Adelaide South Australia 5000
3. The Basil Hetzel Institute, Woodville Rd, Woodville South Australia 5011
4. Previous Chair, Inflammatory Bowel Disease Faculty, Gastroenterological Society of Australia (GESA).

5. Previous Chair, Gastroenterological Network of Intestinal Ultrasound (GENIUS)

Main Scientific Publications

1. Bogatic D, Costello SP, **Bryant RV**. Letter: Dose and Donor Matter-Determining the Optimal Strategy for Faecal Microbiota Transplantation in *Clostridioides difficile* Infection. *Aliment Pharmacol Ther*. 2026 Mar 17. doi: 10.1111/apt.70625.
2. Jairath V, Vuyyuru SK, Zou G, Ma C, Neustifter B, Agboton C, Romo Bautista I, Allocca M, An YK, Begun J, **Bryant RV**, Danese S, Dubinsky M, Feagan BG, Freire M, Novak KL, Panaccione R, Pudipeddi A, Rubin DT, Sands BE, Sparrow MP, Taylor SA, Gecse KB, Wilkens R, Maaser C. Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial. *BMJ Open Gastroenterol*. 2026 Feb 20;13(1):e002088. doi: 10.1136/bmjgast-2025-002088.
3. Plush S, **Bryant RV**, Davis RH, Kumar S, Day AS. Nutrient requirements for adults with ulcerative colitis over the disease course: a systematic scoping review. *Crit Rev Food Sci Nutr*. 2026 Feb 6:1-12. doi: 10.1080/10408398.2026.2620433.
4. Davis RH, **Bryant RV**, Gibson PR, Day AS. The fate of dietary protein in the gastrointestinal tract and implications for colonic disease. *Nat Rev Gastroenterol Hepatol*. 2026 Jan 22. doi: 10.1038/s41575-026-01173-0.
5. Bogatic D, Sparrow MP, Boyapati RK, **Bryant RV**. Balancing costs and care: evaluating the need for novel therapies for immune-mediated inflammatory diseases in Australia. *Intern Med J*. 2026 Jan;56(1):116-121. doi: 10.1111/imj.70258.
6. Mathias RM, Bogatic D, **Bryant RV**. Editorial: Is Disease Clearance the Target in Ulcerative Colitis or a Stride Too Far? *Aliment Pharmacol Ther*. 2025 Dec;62(11-12):1220-1221. doi: 10.1111/apt.70291.
7. Kamath S, **Bryant RV**, Costello SP, Day AS, Forbes B, Haifer C, Hold G, Kelly CR, Li A, Pakuwal E, Stringer A, Tucker EC, Wardill HR, Joyce P. Translational strategies for oral delivery of faecal microbiota transplantation. *Gut*. 2025 Nov 10;74(12):2096-2117. doi: 10.1136/gutjnl-2025-335077.
8. Raja SS, Costello SP, Rayner CK, Day A, Portmann L, Uylaki W, Wheeler R, Saxon S, Tucker EC, Fon J, Edwards S, Young RB, Forster SC, Goodsall T, **Bryant RV**. Examining the role of fecal microbiota transplantation for inducing remission in resistant ulcerative proctitis and distal ulcerative colitis (ulcerative proctitis-fecal microbiota transplantation). *J Crohns Colitis*. 2025 Nov 8;19(10):jjaf169. doi: 10.1093/ecco-jcc/jjaf169.
9. Day AS, Slater R, Young RB, Wheeler RZ, Marcelino VR, Maddigan NK, Forster SC, Costello SP, Uylaki W, Probert CSJ, Andrews JM, Yao CK, Gibson PR, **Bryant RV**. Functional Profiling Demonstrates That a Sulfide-Reducing Diet Achieves Microenvironmental Targets in Ulcerative Colitis. *Inflamm Bowel Dis*. 2025 Nov 1;31(11):3160-3171. doi: 10.1093/ibd/izaf177.
10. Law CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, Seth S, Hanžel J, Ma C, Colombel JF, Levine AC, Spencer EA; CORE-IBD Collaborators. Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion. *Inflamm Bowel Dis*. 2025 Nov 1;31(11):3077-3092. doi: 10.1093/ibd/izaf136.
11. Hanžel J, Solitano V, Vuyyuru SK, Panaccione R, Sands BE, Peyrin-Biroulet L, Danese S, D'Haens GR, Atreya R, Allez M, Bernstein CN, Bossuyt P, Bressler B, **Bryant RV**, Cohen BL, Colombel JF, D'Amico F, Dignass A, Dubinsky M, Fleshner P, Geary RB, Hanauer SB, Hart AL, Kayal M, Kucharzik T, Lakatos PL, Louis E, Magro F, Narula N, Leong RW, Panés J, Raine T, Ran Z, Regueiro MD, Reinisch W, Singh S, Steinhart AH, Travis S, Ungaro RC, van der Woude CJ, Yamamoto T, Ahuja V, Rubin DT, Dulai PS, Cornfield LJ, Hogan M, Sandborn WJ, Feagan BG, Jairath V, Ma C. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory

12. Mathias RM, Goodsall TM, Parker CE, Day AS, An YK, Baraty B, Basnayake C, Begun J, Boyapati RK, Burgell R, Dolinger MT, Maconi G, Novak KL, Sagami S, Smith RL, Srinivasan AR, Taylor SA, Jairath V, Ma C, **Bryant RV**. Editorial: Intestinal Ultrasound for the Assessment of Constipation-Out of the Shadows? Authors' Reply. *Aliment Pharmacol Ther*. 2025 Oct;62(8):855-856. doi: 10.1111/apt.70338.
13. Mathias RM, Goodsall TM, Parker CE, Day AS, An YK, Baraty B, Basnayake C, Begun J, Boyapati RK, Burgell R, Dolinger MT, Maconi G, Novak KL, Sagami S, Smith RL, Srinivasan AR, Taylor SA, Jairath V, Ma C, **Bryant RV**. Expert Position Statement: Defining the Role of Intestinal Ultrasound in Assessing Constipation and Faecal Loading. *Aliment Pharmacol Ther*. 2025 Oct;62(8):799-808. doi: 10.1111/apt.70250.
14. Day AS, **Bryant RV**. Letter: Diet to Modify Risk of IBD-More Plants and Less Processed Food? *Aliment Pharmacol Ther*. 2025 Sep;62(5):557-558. doi: 10.1111/apt.70167.
15. Griffiths BJ, Desborough MJR, Duijvestein M, D'Haens GRA, Yuan Y, **Bryant RV**, Curry N, Travis SPL, Jairath V. Hypercoagulation After Hospital Discharge in Acute Severe Ulcerative Colitis: A Prospective Study. *Clin Gastroenterol Hepatol*. 2025 Sep;23(10):1798-1807.e5. doi: 10.1016/j.cgh.2024.10.031.
16. Goodsall TM, An YK, Andrews JM, Begun J, Friedman AB, Lee A, Lewindon PJ, Spizzo P, Rodgers N, Taylor KM, White LS, Wilkens R, Wright EK, Zou L, Maguire BR, Parker CE, Rémillard J, Novak KL, Panaccione R, Feagan BG, Jairath V, Ma C, **Bryant RV**. Reliability of Intestinal Ultrasound for Evaluating Crohn's Disease Activity Using Point-of-care and Central Reading. *Clin Gastroenterol Hepatol*. 2025 Aug;23(9):1600-1611.e9. doi: 10.1016/j.cgh.2024.08.007.
17. Portmann LJ, Fitzpatrick JA, Halmos EP, **Bryant RV**, Day AS. Looking Beyond Nutrients, How to Assess Diet Quality in an Inflammatory Bowel Disease Population-A Narrative Review.. *Nutrients*. 2025 Jul 17;17(14):2343. doi: 10.3390/nu17142343.
18. De Sciscio M, **Bryant RV**, Haylock-Jacobs S, Day AS, Pitchers W, Iansek R, Costello SP, Kimber TE. Faecal microbiota transplant in Parkinson's disease: pilot study to establish safety & tolerability. *NPJ Parkinsons Dis*. 2025 Jul 9;11(1):203. doi: 10.1038/s41531-025-01061-5.
19. Chu MKW, Day AS, Bogatic D, Hatzi M, Chu SKS, Costello SP, **Bryant RV**. Frequent Dietetic Involvement Enhances Adherence and Clinical Outcomes of Exclusive Enteral Nutrition in Adults With Crohn's Disease. *JGH Open*. 2025 Jul 3;9(7):e70207. doi: 10.1002/jgh3.70207.
20. Chu MKW, Day AS, Broad L, Costello SP, Edwards S, **Bryant RV**. Letter: Exclusive Enteral Nutrition in Ulcerative Colitis-The Path Ahead Needs Careful Consideration. Authors' Reply. *Aliment Pharmacol Ther*. 2025 May;61(9):1579-1580. doi: 10.1111/apt.70121.
21. Fehily SR, Wright EK, Basnayake C, Wilson-O'Brien AL, Stanley A, Marks EP, Russell EE, Hamilton AL, **Bryant RV**, Costello SP, Kamm MA. Faecal microbiota transplantation in Crohn's disease: an Australian randomised placebo-controlled trial protocol. *BMJ Open*. 2025 Apr 19;15(4):e094714. doi: 10.1136/bmjopen-2024-094714.
22. Li A, Costello SP, **Bryant RV**, Haylock-Jacobs S, Haifer C, Lee C, Yeung D, Giri P, Blunt D, Bowen JB, Ryan FJ, Yong A, Wardill HR. A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study. *BMC Cancer*. 2025 Apr 10;25(1):656. doi: 10.1186/s12885-025-14057-4.
23. Day AS, Ballard TM, Yao CK, Gibson PR, **Bryant RV**. Food-Based Interventions as Therapy for Inflammatory Bowel Disease: Important Steps in Diet Trial Design and Reporting of Outcomes. *Inflamm Bowel Dis*. 2025 Apr 10;31(4):1121-1137. doi: 10.1093/ibd/izae185.
24. Tucker EC, Angelica B, Mathias RM, Edwards L, **Bryant RV**, Costello SP. Outcomes of Fecal Microbiota Transplantation for *Clostridioides difficile* Infection in South Australia. *Open Forum Infect Dis*. 2025 Mar 13;12(4):ofaf149. doi: 10.1093/ofid/ofaf149.

25. Yao CK, Green K, Day AS, Ardalan ZM, Slater R, **Bryant RV**, Gibson PR, Probert C. Distinct profiles of fecal volatile organic compounds discriminate ulcerative colitis patients with an ileoanal pouch from those with an intact colon. *Mol Nutr Food Res*. 2025 Feb 28:e70003. doi: 10.1002/mnfr.70003.
26. Chu MKW, Day AS, Broad L, Costello SP, Edwards S, **Bryant RV**. Meta-analysis: exclusive enteral nutrition in adults with ulcerative colitis. *Aliment Pharmacol Ther*. 2025 Mar;61(5):756-775. doi: 10.1111/apt.18495.
27. Griffiths BJ, Desborough MJR, Duijvestein M, D'Haens GRA, Yuan Y, **Bryant RV**, Curry N, Travis SPL, Jairath V. Hypercoagulation after hospital discharge in acute severe colitis: a prospective study. *Clin Gastroenterol Hepatol*. 2024 Dec 16:S1542-3565(24)01085-1. doi: 10.1016/j.cgh.2024.10.031.
28. Mathias RM, Plush SL, Fairhead EJS, Ngoi B, Edwards L, Day AS, **Bryant RV**. Patients with functional gastrointestinal disorders spend less time in tertiary care when managed by a single clinician: results of a multicentre audit in South Australia. *Intern Med J*. 2025 Feb;55(2):260-269. doi: 10.1111/imj.16591.
29. Lu C, Rosentreter R, Parker CE, Remillard J, Wilson SR, Baker ME, Bhatnagar G, Begun J, Bruining DH, **Bryant RV**, Christensen B, Feagan BG, Fletcher JG, Gordon I, Henderson G, Jairath V, Knudsen J, Kucharzik T, Lesack K, Maaser C, Maconi G, Novak K, Rimola J, Taylor SA, Wilkens R, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium. International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement. *Lancet Gastroenterol Hepatol*. 2024 Dec;9(12):1101-1110. doi: 10.1016/S2468-1253(24)00265-6. Epub 2024 Oct 22.
30. Bogatic D, **Bryant RV**. Letter: Gut microbiota- an overlooked therapeutic target in the prevention of post-operative recurrence of Crohn's disease. *Aliment Pharmacol Ther*. 2024 Nov;60(10):1501-1502. doi: 10.1111/apt.18258.
31. Barnes A, **Bryant RV**, Mukherjee S, Andrews JM, Bampton P, Fraser RJ, Mountfield R. Depression influences fatigue in inflammatory bowel disease amongst other factors: a structural modelling approach. *Therap Adv Gastroenterol*. 2024 Sep 2;17:17562848241271987. doi: 10.1177/17562848241271987. eCollection 2024.
32. Goodsall TM, An YK, Andrews JM, Begun J, Friedman AB, Lee A, Lewindon PJ, Spizzo P, Rodgers N, Taylor KM, White LS, Wilkens R, Wright EK, Zou L, Maguire BR, Parker CE, Rémillard J, Novak KL, Panaccione R, Feagan BG, Jairath V, Ma C, **Bryant RV**. Reliability of intestinal ultrasound for evaluating Crohn's disease activity using point-of-care and central reading. *Clin Gastroenterol Hepatol* 2024:S1542-3565(24). doi: 10.1016/j.cgh.2024.08.007
33. Barnes A, **Bryant RV**, Mukherjee S, Spizzo P, Mountfield R. Sleep quality if associated with reduced quality of life in inflammatory bowel disease through its interaction with pain. *JGH Open*. 2024 Aug 24;8(8):e70021. doi: 10.1002/jgh3.70021. eCollection 2024 Aug. PMID: 39185482
34. Day AS, Ballard TM, Yao CK, Gibson PR, **Bryant RV**. Food-based interventions as therapy for inflammatory bowel disease: important steps in diet trial design and reporting of outcomes. *Inflamm Bowel Dis*. 2024 Aug 23:izae185. doi: 10.1093/ibd/izae185. Online ahead of print. PMID: 39177975
35. Little RD, McKenzie J, Srinivasan A, Hilley P, Gilmore RB, Chee D, Sandhu M, Saitta D, Chow E, Thin L, Walker GJ, Moore GT, Lynch K, Andrews J, An YK, **Bryant RV**, Connor SJ, Garg M, Wright EK, Hold G, Segal JP, Boussioutas A, De Cruz P, Ward MG, Sparrow MP. Switching from dose-intensified intravenous to subcutaneous infliximab in inflammatory bowel disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial. *BMJ Open*. 2024 Jul 20;14(7):e081787. doi: 10.1136/bmjopen-2023-081787.
36. Bogatic D, **Bryant RV**. Letter: Microbial manipulation for primary sclerosing cholangitis- associated inflammatory bowel disease- hope on the horizon. *Aliment Pharmacol Ther*. 2024 Aug;60(4):535-536. doi: 10.1111/apt.18098. Epub 2024 Jul 16.
37. Melton SL, Day AS, **Bryant RV**, Halmos EP. Revolution in diet therapy for inflammatory bowel disease. *JGH Open*. 2024 Jul 2;8(7):e13097. doi: 10.1002/jgh3.13097. eCollection 2024 Jul.
38. Mathias RM, Chu MKW, Edwards S, Day AS, Ma C, Jairath V, **Bryant RV**. Editorial: Sonographic assessment of colonic content- a new tool for constipation? Author's reply. *Aliment Pharmacol Ther*. 2024 Jul;60(2):296-297. doi: 10.1111/apt.18109. Epub 2024 Jun 7.

39. Schubert JP, Tay A, Lee KHC, Leong LEX, Rayner CK, Warner MS, Roberts-Thomson IC, Costello SP, **Bryant RV**. Genomic analysis of *Helicobacter pylori* in Australia: Antimicrobial resistance, phylogenetic patterns, and virulence factors. *Gastroenterol Hepatol*. 2024 May 29. doi: 10.1111/jgh.16636. Online ahead of print.
40. Mathias RM, Chu MKW, Edwards S, Day AS, Ma C, Jairath V, **Bryant RV**. Meta-analysis: intestinal ultrasound to evaluate colonic contents and constipation. *Aliment Pharmacol Ther*. 2024 Jul;60(1):6-16. doi: 10.1111/apt.18029. Epub 2024 May 15.
41. Barnes A, Toson B, **Bryant RV**, Mukherjee S, Andrews JM, Spizzo P, Mountfield R. Latent profiles of fatigue in inflammatory bowel disease. *BMC Gastroenterol*. 2024 Apr 30;24(1):148. doi: 10.1186/s12876-024-03239-2.
42. Schubert JP, Ingram PR, Warner MS, Rayner CK, Roberts-Thomson IC, Costello SP, **Bryant RV**. Author reply to Hettiarachchi et al (re *Helicobacter pylori* resistance in Australia) *Intern Med J*. 2024 Feb;54(2):356-357. doi: 10.1111/imj.16333.
43. Li A, Bowen JM, Ball IA, Wilson S, Yong A, Yeung DT, Lee CH, **Bryant RV**, Costello SP, Ryan FJ, Wardill HR. Autologous faecal microbiota transplantation to improve outcomes of haematopoietic stem cell transplantation: results of a single centre study. *Biomedicines* 2023; 11(12):3274.
44. Barnes A, Andrews JM, Mukherjee S, **Bryant RV**, Bampton P, Spizzo P, Fraser RJ, Mountfield R. Simple novel screening tool for obstructive sleep apnoea in inflammatory bowel disease. *Crohns Colitis* 2023; 17(5):otad016.
45. Tucker EC, Haylock-Jacobs S, Rapaic M, Dann LM, **Bryant RV**, Costello SP. Stool donor screening within a Therapeutic Goods Administration compliant donor screening program for faecal microbiota transplantation. *JGH Open*; 7(3):172-177.
46. **Bryant RV**, Travis SPL. APOLLO has landed: PROMS and Histology in UC. *J Crohns Colitis* 2023; jjad040.
47. Goodsall TM, Day AS, Andrews JM, Ruszkiewicz A, Ma C, **Bryant RV**. Composite assessment using intestinal ultrasound and calprotectin is accurate in predicting histological activity in ulcerative colitis: a cohort study. *Inflamm Bowel Disease* 2023; Mar 16:izad043.
48. Pudipeddi A, Fung C, Christensen B, **Bryant RV**, Subramaniam K, Chetwood J, Paramsothy S, Leong RW. Knowledge and attitudes towards the use of histological assessments in ulcerative colitis by gastroenterologists vs pathologists. *World J Gastroenterol* 2023; 29(2): 378-389.
49. Raja SS, **Bryant RV**, Costello SP, Barnett M, Schubert J, Rayner CK. Systematic review of therapies for refractory ulcerative proctitis. *J Gastroenterol Hepatol* 2023 38(4); 496-509.
50. Schubert JP, Rayner CK, Costello SP, Roberts-Thomson IC, Forster SC, **Bryant RV**. *Helicobacter pylori*: have potential benefits been overlooked? *JGH Open* 2022; 6(11):735-737.
51. Bogatic D, **Bryant RV**, Lynch KD, Costello SP. Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis. *Aliment Pharmacol Ther* 2023; 57(1):23-36.
52. CORE-IBD Collaborators; Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, **Bryant RV**, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Geary RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V. CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomised controlled trials in inflammatory disease. *Gastroenterology* 2022;163(4):950-964.
53. Al-Ani AH, Vaughan R, Christensen B, **Bryant RV**, Novak KL. Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease. *Br J Radiol* 2022; 95(1137):20211174.

54. Gulliver EL, Young RB, Chonwerawong M, D'Adamo GL, Thomason T, Widdop JT, Rutten EL, Rossetto Marcelino V, **Bryant RV**, Costello SP, O'Brien CL, Hold GL, Giles EM, Forster SC. Review article: the future of microbiome-based therapeutics. *Aliment Pharmacol Ther* 2022; 56(2):192-208.
55. Duong TA, **Bryant RV**, Andrews JM, Lynch KD. Attitudes towards COVID-19 vaccination in patients with inflammatory bowel disease. *Intern Med J* 2022; 52(6): 1070-1074.
56. Lee SZ, Schubert JP, Prowse SJB, **Bryant RV**. Are we underutilising computer tomography colonography in Australia? *Intern Med J* 2022; 52(5):864-867.
57. Day AS, Yao CK, Costello SP, Ruszkiewicz A, Andrews JM, Gibson PR, Bryant RV. Therapeutic potential of the 4 strategies to sulphide reduction (4-SURE) diet in adults with mild to moderately active ulcerative colitis: an open-label feasibility study. *Journal of Nutrition* 2022 152(7): 1690-1701.
58. Schubert JP, Woodman RJ, Mangoni AA, Rayner CK, Warner MS, Roberts-Thompson I, Costello SP, **Bryant RV**. Geospatial analysis of *Helicobacter pylori* infection in South Australia: should location influence eradication therapy? *J Gastroenterol Hepatol* 2022; PMID35315547 (online ahead of print)
59. Schubert JP, Warner MS, Rayner CK, Roberts Thompson IC, Mangoni AA, Costello SP, **Bryant RV**. Increasing *Helicobacter pylori* clarithromycin resistance in Australia over 20 years. *Intern Med J*. 2021; PMID 34865299 (online ahead of print)
60. Kucharzik T, Tielbeek J, Carter D, Taylor SA, Tolan D, Wilkens R, **Bryant RV**, Hoeffel C, De Kock I, Maaser C, Maconi G, Novak K, Rafaelsen SR, Scharitzer M, Spinelli A, Rimola J. ECCO-ESGAR topical review on optimising reporting for cross-sectional imaging in IBD. *J Crohns Colitis*. 2021. (online ahead of print).
61. Ilvemark JFKF, Hansen T, Goodsall TM, Seidelin JB, Al-Farhan H, Allocca M, Begun J, **Bryant RV**, Carter D, Christensen B, Dubinsky MC, Gecse KB, Kucharzik T, Lu C, Maaser C, Maconi G, Nylund K, Palmela C, Wilson SR, Novak K, Wilkens R. Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement. *J Crohns Colitis*. 2021 (Online ahead of print)
62. **Bryant RV**, Day AS, McGrath KC, Telfer K, Yao CK, Costello SP. Fecal microbiota transplantation augmented by a sulfide-reducing diet for refractory ulcerative colitis: a case report with functional metagenomic analysis. *JGH Open*. 2021 Jul 29;5(9):1099-1102.
63. Day AS, Yao CK, Costello SP, Andrews JM, **Bryant RV**. Food avoidance, restrictive eating behaviour and association with quality of life in adults with inflammatory bowel disease: a systematic scoping review. *Appetite*. 2021 Dec 1;167:105650. doi: 10.1016/j.appet.2021.105650. Epub 2021 Aug 12.
64. Santos-Paulo S, Costello SP, Forster SC, Travis SP, **Bryant RV**. The gut microbiota as a therapeutic target for obesity: a scoping review. *Nutr Res Rev*. 2021 Jun 8:1-14. doi: 10.1017/S0954422421000160. Online ahead of print.PMID: 34100344
65. Day AS, Yao CK, Costello SP, Andrews JM, **Bryant RV**. Food-related quality of life in adults with inflammatory bowel disease is associated with restrictive eating behaviour, disease activity and surgery: a prospective multicentre study. *J Hum Nutr Diet*. 2021 May 18. doi: 10.1111/jhn.12920. Online ahead of print.
66. Soo WT, Costello SP, **Bryant RV**. Dialling back M for monoclonal: successful de-escalation of dose-intensified anti-tumour necrosis factor therapy in inflammatory bowel disease. *Dig Dis Sci*. 2021 Mar 25. doi: 10.1007/s10620-021-06946-y. Online ahead of print.
67. Goodsall TM, Jairath V, **Bryant RV**, Ma C. Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials – is it ready for prime time yet? Authors' reply. *Aliment Pharmacol Ther*. 2021 Apr;53(8):948-949. doi: 10.1111/apt.16313.
68. Goodsall TM, Jairath V, Feagan BG, Parker CE, Nguyen TM, Guizzetti L, Asthana AK, Begun J, Christensen B, Friedman AB, Kucharzik T, Lee A, Lewindon PJ, Maaser C, Novak KL, Rimola J, Taylor KM, Taylor SA, White LS,

- Wilkens R, Wilson SR, Wright EK, **Bryant RV**, Ma C. Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. *Aliment Pharmacol Ther.* 2021 Apr;53(8):873-886.
69. Ma C, Sedano R, Almradi A, Castele NV, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, **Bryant RV**, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. An international consensus to standardise integration of histopathology in Ulcerative colitis clinical trials. *Gastroenterology.* 2021 Jun;160(7):2291-2302.
70. Day AS, Davis R, Costello SP, Yao CK, Andrews JM, **Bryant RV**. The adequacy of habitual fibre intake in individuals with inflammatory bowel disease: a systematic review. *J Acad Nutr Diet.* 2021 Apr;121(4):688-708.e3.
71. Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, **Bryant RV**. Antibiotic resistance of helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis. *J Gastroenterol Hepatol.* 2020. Nov. Online ahead of print. PMID: 33217029.
72. Gill M, Blacketer C, Chitti F, Telfer K, Papanicolas L, Dann LM, Tucker EC, **Bryant RV**, Costello SP. Physician and patient perceptions of fecal microbiota transplant for recurrent or refractory Clostridioides difficile in the first 6 years of a central stool bank. *JGH Open;* 4(5):950-957.
73. Goodsall TM, Han S, **Bryant RV**. Understanding attitudes, concerns, and health behaviours of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. *J Gastroenterol Hepatol* 2020. Online ahead of print.
74. Davis R, Day A, Barrett J, Vanlint A, Andrews JM, Costello SP, **Bryant RV**. Habitual dietary fibre intake is inadequate in patients with inflammatory bowel disease: findings from a multicentre cross-sectional study. *J Hum Nutr Diet.* 2020. Online ahead of print.
75. Meyer EJ, Mignone E, Hade A, Thiruvankatarajan V, **Bryant RV**, Jesudason D. Periprocedural euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitor therapy during colonoscopy. *Diabetes Care* 2020; 43 (11): e181-184.
76. Day AS, Wood JA, Halmos EP, **Bryant RV**. Practical guidance for dietary management of patients with inflammatory bowel disease during the SARS-CoV2 pandemic. *J Acad Nutr Diet* 2020:S2212-2671.
77. Costello SP, Day, A, Yao CK, **Bryant RV**. Faecal microbiota transplantation (FMT) with dietary therapy for acute severe colitis. *BMJ Case rep* 2020; 13(8): e233135.
78. Goodsall TM, Costello SP, **Bryant RV**. ABC of topical therapy in inflammatory bowel disease. *JGH Open* 2020; 4(4):556-557.
79. Vanlint AS, Kaazan P, Kwok M, **Bryant RV**, Ooi M, Bak N, Costello S. Lessons from practice: low attenuation lymphadenopathy on computed tomography leading to diagnosis of Whipple disease. *Med J Aust* 2020; 213(4):161-162.
80. Aysha AA, Rentsch C, Prentice R, Johnson D, **Bryant RV**, Ward MG, Costello SP, Lewindon P, Ghaly S, Connor SJ, Begun J, Christensen B. Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. *Intern Med J* 2020; 50(7): 798-804.
81. Goodsall TM, Nguyen TM, Parker CE, Ma C, Andrews JM, Jairath V, **Bryant RV**. Systematic review: Gastrointestinal ultrasound scoring indices for inflammatory bowel disease. *J Crohns Colitis.* 2020. Online ahead of print. PMID: 3261438
82. Goodsall TM, Costello SP, **Bryant RV**. Histological Healing in Ulcerative Colitis: Near Enough is Not Good Enough. *J Crohns Colitis.* Online ahead of print. PMID: 32602550
83. Goodsall TM, Costello SP, **Bryant RV**. Coronavirus disease 2019 (COVID-19) and implications for thiopurine use. *Med J Aust.* 2020: 10; 490-490.

84. Soo WT, **Bryant RV**, Costello SP. Faecal microbiota transplantation: indications, evidence and safety. *Aust Prescr*. 2020 Apr;43(2):36-38.
85. Flanagan E, Wright EK, Begun J, **Bryant RV**, An YK, Ross AL, Kiburg KV, Bell SJ. Monitoring Inflammatory Bowel Disease in Pregnancy using Gastrointestinal Ultrasonography. *J Crohns Colitis*. 2020; 14(10): 1405-1412.
86. Rajagopalan A, Rajagopalan, A, Van De Ven L, Martin S; Fon, J, Costello SP, **Bryant RV**. Gastrointestinal ultrasound in inflammatory bowel disease care: patient perceptions and impact on disease-related knowledge. *JGH Open* 2019 Oct 9;4(2):267-272.
87. Sathanathan D, Rajagopalan, A, Van De Ven L, Martin S; Fon, J, Costello SP, **Bryant RV**. Point of care gastrointestinal ultrasound in inflammatory bowel disease: an accurate alternative for disease monitoring. *JGH Open* 2019 Oct 9;4(2):273-279.
88. Goodsall, TM, Noy R, Nguyen TM, Costello SP, JairathV, **Bryant RV**. Systematic Review: Patient Perceptions of Monitoring Tools in Inflammatory Bowel Disease, *Journal of the Canadian Association of Gastroenterology*, 2020; 4(2): E31-41
89. Costello SP, **Bryant RV**. Editorial: faecal microbiota transplantation-the silver bullet for severe and fulminant Clostridioides difficile infection? *Aliment Pharmacol Ther*. 2020 Jan;51(1):180-181.
90. Day A, Melton S, Wood J, **Bryant RV**. Exclusive Enteral Nutrition: An optimal care pathway for use in adult patients with active Crohn's disease. *JGH Open* 2019;4(2):260-266.
91. Roberts-Thomson IC, **Bryant RV**, Costello SP. Uncovering the cause of ulcerative colitis. *JGH Open*. 2019 Aug 6;3(4):274-276.
92. Biswas S, **Bryant RV**, Travis S. Interfering with leukocyte trafficking in Crohn's disease. *Best Pract Res Clin Gastroenterol*. 2019 Feb - Apr;38-39:101617.
93. **Bryant RV**, Costello SP. Editorial: assessing histological disease activity in Crohn's disease- a call for standardisation of mucosal biopsy location. *Aliment Pharmacol Ther*. 2019 Jul;50(1):103-104.
94. Wardill HR, Secombe KR, **Bryant RV**, Hazenberg MD, Costello SP. Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients. *EBioMedicine*. 2019 Jun;44:730-740.
95. Costello SP, **Bryant RV**. Faecal microbiota transplantation in Australia: bogged down in regulatory uncertainty. *Intern Med J*. 2019 Feb;49(2):148-151.
96. Costello SP, Hughes PA, Waters O, **Bryant RV**, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients with Ulcerative Colitis: A Randomised Controlled Trial. *JAMA*. 2019 Jan 15;321(2):156-164.
97. Oakland K, Kahan BC, Guizzetti L, Martel M, **Bryant RV**, Brahmania M, Singh S, Nguyen NQ, Sey MSL, Barkun A, Jairath V. Development, Validation, and Comparative Assessment of International Scoring System to Determine Risk of Upper gastrointestinal Bleeding. *Clin Gastroenterol Hepatol*. 2019 May;17(6):1121-1129.
98. **Bryant RV**, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM. Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behaviour, Fecal Calprotectin, and Quality of Life. *Inflamm Bowel Dis*. 2019 May 4;25(6):e62-e63.
99. **Bryant RV**, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM. Obesity in inflammatory bowel disease: gains in adiposity despite high prevalence of myopenia and osteopenia. *Nutrients* 2018;10(9):1192.

100. **Bryant RV**, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM. Visceral adipose tissue is associated with stricturing Crohn's disease behavior, faecal calprotectin and quality of life. *Inflammatory Bowel Diseases* 2018;25(3):592-600.
101. **Bryant RV**, Friedman AB, Wright EK, Taylor KM, Begun J, Maconi G, Maaser C, Novak K, Kucharzik T, Atkinson NSS, Asthana AK, Gibson PR. Review article: Gastrointestinal ultrasound in inflammatory bowel disease: an underutilised resource with potential paradigm-changing application. *Gut* 2018; 67:973-985.
102. Atkinson NSS, **Bryant RV**, Dong Y, Maaser C, Kucharzik T, Maconi G, Asthana AK, Blaivas M, Goudie A, Gilja OH, Nuernberg D, Schreiber-Dietrich D, Dietrich CF. How to perform gastrointestinal ultrasound: Anatomy and normal findings. *World J Gastroenterol.* 2017 Oct 14;23(38):6931-6941.
103. Schwerd T & **Bryant RV**, Pandey S, Capitani M, Meran L, Cazier JB, Jung J, Mondal K, Parkes M, Mathew CG, Fiedler K, McCarthy DJ; WGS500 Consortium; Oxford IBD cohort study investigators; COLORS in IBD group investigators; UK IBD Genetics Consortium, Sullivan PB, Rodrigues A, Travis SPL, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J; INTERVAL Study, Russell RK, Wilson DC, Kelsen JR, Cornall R, Denson LA, Kugathasan S, Knaus UG, Serra EG, Anderson CA, Duerr RH, McGovern DP, Cho J, Powrie F, Li VS, Muise AM, Uhlig HH. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. *Mucosal Immunol.* 2018;11(2):562-574.
104. Mitrev N, Vande Castele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, **Bryant R**, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountfield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. *Aliment Pharmacol Ther.* 2017 Dec;46(11-12):1037-1053.
105. **Bryant RV**, Prowse S, Nguyen-Hoang A, Lewis MC. Gastrointestinal: Adenocarcinoma in ileal Crohn's disease: A devil in disguise. *J Gastroenterol Hepatol* 2017; 32(9): 1535.
106. **Bryant RV**, Costello SP, Schoeman S, Sathanathan D, Knight E, Lau SY, Schoeman MN, Mountfield R, Tee D, Travis SPL, Andrews JM. Limited uptake of ulcerative colitis 'treat to target' recommendations in real-world practice. *J Gastroenterol Hepatol* 2018;33(3):599-607.
107. Costello SP, Soo W, **Bryant RV**, Jairath V, Hart AL, Andrews JM. Editorial: faecal microbiota transplantation for ulcerative colitis- not quite there yet? Authors' reply. *Aliment Pharmacol Ther* 2017;46(6):631-632.
108. Costello SP, Soo W, **Bryant RV**, Jairath V, Hart AL, Andrews JM. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. *Aliment Pharmacol Ther.* 2017 Aug;46(3):213-224.
109. Bezzio C, **Bryant RV**, Manes G, Maconi G, Saibeni S. New horizons in the imaging of perianal Crohn's disease: transperineal ultrasonography. *Expert Rev Gastroenterol Hepatol* 2017;11(6):523-530.
110. Guirgis M, Wendt E, Wang LM, Walsh A, Burger D, **Bryant RV**, Kent A, Adamson R, Brain O, Travis SPL, Keshav S. Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. *J Crohns Colitis* 2017;11(4):460-467.
111. Atkinson SS, **Bryant RV**, Dong Y, Maaser C, Kucharzik T, Maconi G, Asthana A, Blaivas M, Goudie A, Gilja OH, Dietrich C. WFUMB Position Paper. Learning intestinal ultrasound: theory and practice. *Ultrasound Med Biol* 2016;42(12):2732-2742.
112. Walsh A & **Bryant RV**, Travis SPL. Current best practice for disease activity assessment in inflammatory bowel disease. *Nature Reviews Gastroenterology and Hepatology* 2016;13(10):567-79.
113. Hughes PA, Costello SP, **Bryant RV**, Andrews JM. Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. *Am J Physiol Gastrointest Liver Physiol* 2016;311(3):G01-13.
114. Bennett AL, Moore, D, Bampton PA, **Bryant RV**, Andrews JM. Outcomes and patients' perspectives of transition from paediatric to adult care in inflammatory bowel disease. *World Journal of Gastroenterology* 2016;22:2611-20.

115. **Bryant RV**, Costello SP, Andrews JM. Editorial: untangling symptoms from mucosal healing in UC – a note of caution for patient reported outcomes. *Alimentary Pharmacology Therapeutics* 2015;42:1327-8.
116. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, **Bryant RV**, D’Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Geary R, Krishnareddy S, Lakatos P, Loftus E, Marteau P, Munkholm P, Murdoch T, Ordas I, Panaccione R, Riddell R, Ruel J, Rubin D, Samaan M, Siegel C, Silverberg M, Stoker J, Schrieber S, Travis SPL, Van Assche G, Danese S, Panes J, Bouguen G, O’Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *American Journal of Gastroenterology* 2015;110:1324-38.
117. **Bryant RV**, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SPL. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. *Gut* 2016;65(3):408-414.
118. **Bryant RV**, Andrews JM. Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease- authors reply. *Alimentary Pharmacology Therapeutics* 2015; 41:1304-5.
119. **Bryant RV**, Winer S, Travis SPL, Riddell RH. Response to Villanacci et al. *Journal of Crohn’s and Colitis* 2015;9:429.
120. **Bryant RV**, Ooi S, Schultz CG, Goess C, Grafton R, Hughes J, Lim A, Bartholomeusz FD, Andrews JM. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics* 2015; 41:895-906.
121. **Bryant RV**, Sandborn WJ, Travis SPL. Introducing vedolizumab to clinical practice: who, when, and how? *Journal of Crohn’s and Colitis* 2015;9:356-366.
122. **Bryant RV**, Brain O, Travis SPL. Conventional therapy for inflammatory bowel disease. *Scandinavian Journal of Gastroenterology* 2015;50:90-112.
123. **Bryant RV**, Winer S, Travis SPL, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. *Journal of Crohn’s and Colitis* 2014;8:1582-97.
124. Griffiths EA, McDonald CR, **Bryant RV**, Devitt PG, Bright T, Holloway RH, Thompson SK. Retrospective analysis of surgery and trans-arterial embolization for major non-variceal upper gastrointestinal bleeding. *ANZ J Surg* 2016;86(5):381-5.
125. **Bryant RV**, Trott MJ, Bennett A, Bampton PA, Moore DJ, Andrews JM. Transition of care in inflammatory bowel disease: mind the gap! Theory, practice and recommendations for an Australian context. *Internal Medicine Journal* 2013;43:1171-6.
126. **Bryant RV**, Jairath V, Curry N, Travis SP. Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk? *Journal of Crohn’s and Colitis* 2014;8:166-71.
127. **Bryant RV**, Kuo P, Williamson K, Yam C, Schoeman MN, Holloway RH, Nguyen NQ. Performance of the Glasgow-Blatchford score in predicting clinical outcomes and intervention in hospitalized patients with upper GI bleeding. *Gastrointestinal Endoscopy* 2013;78:576-83.
128. **Bryant RV**, Trott MJ, Bartholomeusz FD, Andrews JM. Systematic review: body composition in adults with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics* 2013;38:213-25.
129. **Bryant RV**, Schoeman SN, Schoeman MN. Shorter preparation to procedure interval for colonoscopy improves quality of bowel cleansing. *Internal Medicine Journal* 2013;43:162-8.
130. **Bryant RV**, Holloway RH, Nguyen NQ. Education and imaging. *Gastrointestinal: Role of endoscopic ultrasound in the evaluation of pseudoachalasia. Journal of Gastroenterology and Hepatology* 2012;27:1128.

AOCC 2026

IMKASID 2026

JUNE 25 (Thu.) - 27 (Sat.), 2026 | COEX, SEOUL, KOREA



-
131. **Bryant RV**, van Langenberg DR, Holtmann GJ, Andrews JM. Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status. *Journal of Gastroenterology and Hepatology* 2011;26:916-23.
132. Andrews JM, **Bryant RV**, van Langenberg DR, Holtmann G. Are all symptoms in patients in IBD due to occult inflammation? *American Journal of Gastroenterology* 2010;105:2703.
-